Insider · CIK 0001441461
Mark A Glickman
Files at MTVA (NeuroBo Pharmaceuticals, Inc.), BSEM (BioStem Technologies, Inc.). First filing -, latest -.
In brief
Mark A Glickman files SEC Form 4 as director at MTVA (NeuroBo Pharmaceuticals, Inc.), and also at BSEM (BioStem Technologies, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Mark A Glickman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | BSEM BioStem Technologies, Inc. | MOption exercise Common Stock | +7,671 | $0.00 | $0 | 7,671 | Aug 28, 2026 |
| Aug 27, 2026 | BSEM BioStem Technologies, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,671 | $0.00 | $0 | 0 | Aug 28, 2026 |
| Jun 8, 2026 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +17,186 | $0.00 | $0 | 20,629 | Jun 8, 2026 |
| Jun 30, 2025 | MTVA NeuroBo Pharmaceuticals, Inc. | AGrant or award Common Stock | +28,147 | $0.00 | $0 | 37,887 | Jul 1, 2025 |
Questions about Mark A Glickman
Answered from the filings on this page, as of the latest one.
Is Mark A Glickman buying or selling?
Mark A Glickman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Mark A Glickman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark A Glickman has 0.
Where does Mark A Glickman file Form 4?
Mark A Glickman has filed Form 4 at MTVA (NeuroBo Pharmaceuticals, Inc.); BSEM (BioStem Technologies, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.